Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 328
2013 396
2014 285
2015 473
2016 530
2017 413
2018 432
2019 291
2020 277
2021 234
2022 199
2023 139
2024 47

Text availability

Article attribute

Article type

Publication date

Search Results

3,576 results

Results by year

Filters applied: . Clear all
Page 1
Memory-like differentiation enhances NK cell responses against colorectal cancer.
Marin ND, Becker-Hapak M, Song WM, Alayo QA, Marsala L, Sonnek N, Berrien-Elliott MM, Foster M, Foltz JA, Tran J, Wong P, Cubitt CC, Pence P, Hwang K, Zhou AY, Jacobs MT, Schappe T, Russler-Germain DA, Fields RC, Ciorba MA, Fehniger TA. Marin ND, et al. Oncoimmunology. 2024 May 7;13(1):2348254. doi: 10.1080/2162402X.2024.2348254. eCollection 2024. Oncoimmunology. 2024. PMID: 38737793 Free PMC article.
Distinct autoantibody profiles across checkpoint inhibitor types and toxicities.
Mu-Mosley H, von Itzstein MS, Fattah F, Liu J, Zhu C, Xie Y, Wakeland EK, Park JY, Kahl BS, Diefenbach CS, Gerber DE. Mu-Mosley H, et al. Oncoimmunology. 2024 May 9;13(1):2351255. doi: 10.1080/2162402X.2024.2351255. eCollection 2024. Oncoimmunology. 2024. PMID: 38737792 Free PMC article. Clinical Trial.
Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes.
Kidman J, Zemek RM, Sidhom JW, Correa D, Principe N, Sheikh F, Fear VS, Forbes CA, Chopra A, Boon L, Zaitouny A, de Jong E, Holt RA, Jones M, Millward MJ, Lassmann T, Forrest ARR, Nowak AK, Watson M, Lake RA, Lesterhuis WJ, Chee J. Kidman J, et al. Oncoimmunology. 2024 Apr 26;13(1):2345859. doi: 10.1080/2162402X.2024.2345859. eCollection 2024. Oncoimmunology. 2024. PMID: 38686178 Free PMC article.
Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses.
Tapia-Galisteo A, Sánchez-Rodríguez I, Narbona J, Iglesias-Hernández P, Aragón-García S, Jiménez-Reinoso A, Compte M, Khan S, Tsuda T, Chames P, Lacadena J, Álvarez-Vallina L, Sanz L. Tapia-Galisteo A, et al. Oncoimmunology. 2024 Apr 13;13(1):2338558. doi: 10.1080/2162402X.2024.2338558. eCollection 2024. Oncoimmunology. 2024. PMID: 38623463 Free PMC article.
Redoxhigh phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma.
Wei XW, Lu C, Zhang YC, Fan X, Xu CR, Chen ZH, Wang F, Yang XR, Deng JY, Yang MY, Gou Q, Mei SQ, Luo WC, Zhong RW, Zhong WZ, Yang JJ, Zhang XC, Tu HY, Wu YL, Zhou Q. Wei XW, et al. Oncoimmunology. 2024 Apr 9;13(1):2340154. doi: 10.1080/2162402X.2024.2340154. eCollection 2024. Oncoimmunology. 2024. PMID: 38601319 Free PMC article.
3,576 results